Search for "bicyclic ring" in Full Text gives 34 result(s) in Beilstein Journal of Organic Chemistry.
Beilstein J. Org. Chem. 2014, 10, 1290–1298, doi:10.3762/bjoc.10.130
Graphical Abstract
Scheme 1: Synthesis of TETs 1 and 2 and TATs 3 and 4.
Scheme 2: Synthesis of triptycenetripropiolic acid (TPA) 5 and 6.
Scheme 3: Synthesis of triphosphinotriptycenes (TPT) 7 and 8.
Figure 1: Nuclease activities of the triptycene derivatives 1–8. Agarose gel (top) shows results of the incub...
Figure 2: Effect of triptycene derivatives on the restriction endonuclease activity of HindIII and BamHI enzy...
Figure 3: (A) Oligomer duplex sequence that was used to study the effect of triptycene derivatives on the aba...
Figure 4: UV–vis spectra showing the hyperchromic effect after addition of ctDNA (20 μM) to 5 and 6 (80 μM).
Figure 5: UV–vis absorption spectra of (A) 2,6,14-trisubstituted triptycene derivatives 1, 3, 5 and 7 in DMSO...
Beilstein J. Org. Chem. 2013, 9, 2265–2319, doi:10.3762/bjoc.9.265
Graphical Abstract
Scheme 1: Scaled industrial processes for the synthesis of simple pyridines.
Scheme 2: Synthesis of nicotinic acid from 2-methyl-5-ethylpyridine (1.11).
Scheme 3: Synthesis of 3-picoline and nicotinic acid.
Scheme 4: Synthesis of 3-picoline from 2-methylglutarodinitrile 1.19.
Scheme 5: Picoline-based synthesis of clarinex (no yields reported).
Scheme 6: Mode of action of proton-pump inhibitors and structures of the API’s.
Scheme 7: Hantzsch-like route towards the pyridine rings in common proton pump inhibitors.
Figure 1: Structures of rosiglitazone (1.40) and pioglitazone (1.41).
Scheme 8: Synthesis of rosiglitazone.
Scheme 9: Syntheses of 2-pyridones.
Scheme 10: Synthesis and mechanism of 2-pyrone from malic acid.
Scheme 11: Polymer-assisted synthesis of rosiglitazone.
Scheme 12: Synthesis of pioglitazone.
Scheme 13: Meerwein arylation reaction towards pioglitazone.
Scheme 14: Route towards pioglitazone utilising tyrosine.
Scheme 15: Route towards pioglitazone via Darzens ester formation.
Scheme 16: Syntheses of the thiazolidinedione moiety.
Scheme 17: Synthesis of etoricoxib utilising Negishi and Stille cross-coupling reactions.
Scheme 18: Synthesis of etoricoxib via vinamidinium condensation.
Figure 2: Structures of nalidixic acid, levofloxacin and moxifloxacin.
Scheme 19: Synthesis of moxifloxacin.
Scheme 20: Synthesis of (S,S)-2,8-diazabicyclo[4.3.0]nonane 1.105.
Scheme 21: Synthesis of levofloxacin.
Scheme 22: Alternative approach to the levofloxacin core 1.125.
Figure 3: Structures of nifedipine, amlodipine and clevidipine.
Scheme 23: Mg3N2-mediated synthesis of nifedipine.
Scheme 24: Synthesis of rac-amlodipine as besylate salt.
Scheme 25: Aza Diels–Alder approach towards amlodipine.
Scheme 26: Routes towards clevidipine.
Figure 4: Examples of piperidine containing drugs.
Figure 5: Discovery of tiagabine based on early leads.
Scheme 27: Synthetic sequences to tiagabine.
Figure 6: Structures of solifenacin (2.57) and muscarine (2.58).
Scheme 28: Enantioselective synthesis of solifenacin.
Figure 7: Structures of DPP-4 inhibitors of the gliptin-type.
Scheme 29: Formation of inactive diketopiperazines from cis-rotameric precursors.
Figure 8: Co-crystal structure of carmegliptin bound in the human DPP-4 active site (PDB 3kwf).
Scheme 30: Improved route to carmegliptin.
Figure 9: Structures of lamivudine and zidovudine.
Scheme 31: Typical routes accessing uracil, thymine and cytosine.
Scheme 32: Coupling between pyrimidones and riboses via the Vorbrüggen nucleosidation.
Scheme 33: Synthesis of lamivudine.
Scheme 34: Synthesis of raltegravir.
Scheme 35: Mechanistic studies on the formation of 3.22.
Figure 10: Structures of selected pyrimidine containing drugs.
Scheme 36: General preparation of pyrimidines and dihydropyrimidones.
Scheme 37: Synthesis of imatinib.
Scheme 38: Flow synthesis of imatinib.
Scheme 39: Syntheses of erlotinib.
Scheme 40: Synthesis of erlotinib proceeding via Dimroth rearrangement.
Scheme 41: Synthesis of lapatinib.
Scheme 42: Synthesis of rosuvastatin.
Scheme 43: Alternative preparation of the key aldehyde towards rosuvastatin.
Figure 11: Structure comparison between nicotinic acetylcholine receptor agonists.
Scheme 44: Syntheses of varenicline and its key building block 4.5.
Scheme 45: Synthetic access to eszopiclone and brimonidine via quinoxaline intermediates.
Figure 12: Bortezomib bound in an active site of the yeast 20S proteasome ([114], pdb 2F16).
Scheme 46: Asymmetric synthesis of bortezomib.
Figure 13: Structures of some prominent piperazine containing drugs.
Figure 14: Structural comparison between the core of aplaviroc (4.35) and a type-1 β-turn (4.36).
Scheme 47: Examplary synthesis of an aplaviroc analogue via the Ugi-MCR.
Scheme 48: Syntheses of azelastine (5.1).
Figure 15: Structures of captopril, enalapril and cilazapril.
Scheme 49: Synthesis of cilazapril.
Figure 16: Structures of lamotrigine, ceftriaxone and azapropazone.
Scheme 50: Synthesis of lamotrigine.
Scheme 51: Alternative synthesis of lamotrigine (no yields reported).
Figure 17: Structural comparison between imiquimod and the related adenosine nucleoside.
Scheme 52: Conventional synthesis of imiquimod (no yields reported).
Scheme 53: Synthesis of imiquimod.
Scheme 54: Synthesis of imiquimod via tetrazole formation (not all yields reported).
Figure 18: Structures of various anti HIV-medications.
Scheme 55: Synthesis of abacavir.
Figure 19: Structures of diazepam compared to modern replacements.
Scheme 56: Synthesis of ocinaplon.
Scheme 57: Access to zaleplon and indiplon.
Scheme 58: Different routes towards the required N-methylpyrazole 6.65 of sildenafil.
Scheme 59: Polymer-supported reagents in the synthesis of key aminopyrazole 6.72.
Scheme 60: Early synthetic route to sildenafil.
Scheme 61: Convergent preparations of sildenafil.
Figure 20: Comparison of the structures of sildenafil, tadalafil and vardenafil.
Scheme 62: Short route to imidazotriazinones.
Scheme 63: Alternative route towards vardenafils core imidazotriazinone (6.95).
Scheme 64: Bayer’s approach to the vardenafil core.
Scheme 65: Large scale synthesis of vardenafil.
Scheme 66: Mode of action of temozolomide (6.105) as methylating agent.
Scheme 67: Different routes to temozolomide.
Scheme 68: Safer route towards temozolomide.
Figure 21: Some unreported heterocyclic scaffolds in top market drugs.
Beilstein J. Org. Chem. 2013, 9, 204–214, doi:10.3762/bjoc.9.24
Graphical Abstract
Figure 1: PLG peptidomimetic design approach. The Φ2, ψ2, Φ3, and ψ3 torsion angles define the postulated β-t...
Figure 2: Lactam-based PLG peptidomimetics.
Figure 3: Lactam-based photoaffinity ligands of the PLG modulatory site.
Figure 4: Bicyclic PLG peptidomimetics.
Figure 5: Spiro-bicyclic PLG peptidomimetics.
Scheme 1: Synthesis of α-alkylaldehyde proline derivatives by Seebach's “self-regeneration of chirality” meth...
Scheme 2: Synthetic approaches to the spiro-bicyclic scaffolds.
Figure 6: Prolyl PLG analogues.
Figure 7: (A) Type VI β-turn mimics. An ethylene bridge connection in 43 and 45 between the α-carbon of the s...
Scheme 3: Synthesis of spiro-bicyclic type VI β-turn mimic 48.
Scheme 4: Biproline formation from Seebach’s oxazolidinone.
Figure 8: Positive and negative allosteric modulators of the D2 dopamine receptor based on the 5.6.5 spiro-bi...
Beilstein J. Org. Chem. 2011, 7, 1622–1635, doi:10.3762/bjoc.7.191
Graphical Abstract
Figure 1: Cyanobacteria proliferate in diverse habitats. A) Bloom-forming freshwater cyanobacteria of the gen...
Figure 2: Schematic representation of enzymatic domains in A) nonribosomal peptide synthetases (NRPS); B) pol...
Figure 3: Structures of NRPS and PKS products in freshwater cyanobacteria.
Figure 4: A) Synthesis of the Adda ((2S,3S,8S,9S)-3-amino-9-methoxy-2,6,8-trimethyl-10-phenyl-4,6-decadienoic...
Figure 5: Structures of NRPS and PKS products in marine cyanobacteria.
Figure 6: A) Formation of the trichloroleucyl starter unit of barbamide (7) synthesis through the non-heme ir...
Figure 7: Structures of NRPS and PKS products in terrestrial cyanobacteria.
Figure 8: Synthesis of the (2S,4S)-4-methylproline moiety of nostopeptolides A (13).
Figure 9: Structures of cyanobacterial peptides that are synthesized ribosomally and post-translationally mod...
Figure 10: Formation of ester linkages and ω-amide linkage in microviridins 17 by the ATP grasp ligases MvdD a...
Figure 11: Structures of cyanobacterial sunscreen compounds.
Beilstein J. Org. Chem. 2011, 7, 717–734, doi:10.3762/bjoc.7.82
Graphical Abstract
Scheme 1: General reactivity of cyclopropenes in the presence of gold catalysts.
Scheme 2: Cationic organogold species generated from cyclopropenone acetals.
Scheme 3: Rotation barriers around the C2–C3 bond (M06 DFT calculations).
Scheme 4: Au–C1 bond length in organogold species of type D.
Scheme 5: Gold-catalyzed addition of alcohols or water to cyclopropene 8.
Scheme 6: Gold-catalyzed addition of alcohols to cyclopropene 10.
Scheme 7: Mechanism of the gold-catalyzed addition of alcohols to cyclopropenes.
Scheme 8: Synthesis of tert-allylic ethers from cyclopropenes and allenes.
Scheme 9: Oxidation of the intermediate gold–carbene with diphenylsulfoxide.
Scheme 10: Gold, copper and Lewis acid-catalyzed reactions of cyclopropene 18.
Scheme 11: Mechanism of the Lewis acid-catalyzed reactions of cyclopropene 18.
Scheme 12: Gold-catalyzed rearrangement of vinylcyclopropenes 25.
Scheme 13: Gold-catalyzed rearrangement of cyclopropenes 27 to indenes 28.
Scheme 14: Gold-catalyzed rearrangement of cyclopropenes 29 to indenes 30.
Scheme 15: Gold-catalyzed rearrangement of cyclopropenyl ester 34a.
Scheme 16: Gold-catalyzed reactions of cyclopropenyl esters 34b–34d.
Scheme 17: Gold-catalyzed reactions of cyclopropenylsilane 34e.
Scheme 18: Gold-catalyzed rearrangement of cyclopropenylmethyl acetates.
Scheme 19: Mechanism of the gold-catalyzed rearrangement of cyclopropenes 39.
Scheme 20: Gold-catalyzed cyclopropanation of styrene with cyclopropene 8.
Scheme 21: Representative reactions of carbene precursors on gold metal.
Scheme 22: Intermolecular olefin cyclopropanation with gold carbenes generated from cyclopropenes.
Scheme 23: Gold-catalyzed formation of trienes from cyclopropenes and furans.
Scheme 24: Gold-catalyzed formation of trienes from cyclopropenes and furans.
Scheme 25: Gold-catalyzed formation of trienes from cyclopropenes and furans.
Scheme 26: Gold-catalyzed cycloisomerization of cyclopropene-ene 59.
Scheme 27: Gold-catalyzed cycloisomerization of substituted allyl cyclopropenyl carbinyl ethers 62a–62f.
Scheme 28: Gold-catalyzed cycloisomerization of cyclopropene-enes.
Scheme 29: Gold-catalyzed cycloisomerization of cyclopropene-ynes.
Scheme 30: Formation of products arising from a double cleavage process in the gold-catalyzed cycloisomerizati...
Scheme 31: Gold-catalyzed cycloisomerization of cyclopropene-ynes involving a double cleavage process.
Scheme 32: Gold-catalyzed reaction of cyclopropene-ynes, cyclopropene-enes and cyclopropene-allenes.
Beilstein J. Org. Chem. 2011, 7, 346–363, doi:10.3762/bjoc.7.45
Graphical Abstract
Scheme 1: Superelectrophilic activation of the acetyl cation.
Scheme 2: Ring opening of diprotonated 2-oxazolines.
Scheme 3: AlCl3-promoted ring opening of isoxaolidine 16.
Scheme 4: Ring-opening reactions of cyclopropyl derivatives.
Scheme 5: Condensations of ninhydrin (28) with benzene.
Scheme 6: Rearrangement of 29 to 30.
Scheme 7: Superacid promoted ring opening of succinic anhydride (33).
Scheme 8: Reaction of phthalic acid (36) in FSO3H-SbF5.
Scheme 9: Ring expansion of superelectrophile 42.
Scheme 10: Reaction of camphor (44) in superacid.
Scheme 11: Isomerization of 2-cyclohexen-1-one (48).
Scheme 12: Isomerization of 2-decalone (51).
Scheme 13: Rearrangement of the acyl-dication 58.
Scheme 14: Reaction of dialkylketone 64.
Scheme 15: Ozonolysis in superacid.
Scheme 16: Rearrangement of 1-hydroxy-2-methylcyclohexane carboxylic acid (79) in superacid.
Scheme 17: Isomerization of the 1,5-manxyl dication 87.
Scheme 18: Energetics of isomerization.
Scheme 19: Rearrangement of dication 90.
Scheme 20: Superacid promoted rearrangement of pivaldehyde (92).
Scheme 21: Rearrangement of a superelectrophilic carboxonium ion 100.
Scheme 22: Proposed mechanism for the Wallach rearrangement.
Scheme 23: Wallach rearrangement of azoxypyridines 108 and 109.
Scheme 24: Proposed mechanism of the benzidine rearrangement.
Scheme 25: Superacid-promoted reaction of quinine (122).
Scheme 26: Superacid-promoted reaction of vindoline derivative 130.
Scheme 27: Charge migration by hydride shift and acid–base chemistry.
Scheme 28: Reactions of 1-hydroxycyclohexanecarboxylic acid (137).
Scheme 29: Reaction of alcohol 143 with benzene in superacid.
Scheme 30: Reaction of alcohol 148 in superacid with benzene.
Scheme 31: Mechanism of aza-polycyclic aromatic compound formation.
Scheme 32: Superacid-promoted reaction of ethylene glycol (159).
Scheme 33: Reactions of 1,3-propanediol (165) and 2-methoxyethanol (169).
Scheme 34: Rearrangement of superelelctrophilic acyl dication 173.
Beilstein J. Org. Chem. 2010, 6, No. 78, doi:10.3762/bjoc.6.78
Graphical Abstract
Figure 1: Natural product and natural product-like hybrids.
Figure 2: Structures of thiolactomycin (1), isatin (2), the desired hybrid 3 and tetracycle 4.
Scheme 1: Reagents and conditions: (a) KOH, MeOH, 25 °C, 95–100% (b) 6, DMF, 60 °C, 9–36%.
Scheme 2: Proposed mechanism for the formation of tetracycles 4.
Figure 3: (a) Molecular structure of the tetracycle 4a. (b) Structure of the dimer of 4a showing the atomic n...
Figure 4: Molecular structure of (a) 4b and (b) 4c, with ellipsoidal model of probability level = 35%.
Beilstein J. Org. Chem. 2010, 6, No. 38, doi:10.3762/bjoc.6.38
Graphical Abstract
Figure 1: Conformational effects associated with C–F bonds.
Figure 2: HIV protease inhibitor Indinavir (17) and fluorinated analogues 18 and 19. In analogue 18 the gauche...
Figure 3: Cholesteryl ester transfer protein inhibitors 20 and 21. In the fluorinated analogue 21, nO→σ*CF hy...
Figure 4: HIV reverse transcriptase inhibitor 22 and acid-stable fluorinated analogues 23–25. The F–C–C–O gau...
Figure 5: Dihydroquinidine (26) and fluorinated analogues 27 and 28. Newman projections along the C9–C8 bonds...
Figure 6: The neurotransmitter GABA (29) and fluorinated analogues (R)-30 and (S)-30. Newman projections of (R...
Figure 7: The insect pheromone 31 and fluorinated analogues (S)-32 and (R)-32. The proposed bioactive conform...
Figure 8: Capsaicin (33) and fluorinated analogues (R)-34 and (S)-34.
Figure 9: Asymmetric epoxidation reaction catalysed by pyrrolidine 35. Inset: the geometry of the activated i...
Figure 10: The asymmetric transannular aldol reaction catalysed by trans-4-fluoroproline (41), and its applica...
Figure 11: The asymmetric Stetter reaction catalysed by chiral NHC catalysts 49–52. The ring conformations of ...
Figure 12: A multi-vicinal fluoroalkane.
Figure 13: X-ray crystal structures of diastereoisomeric multi-vicinal fluoroalkanes 55 and 56. The different ...
Figure 14: Examples of fluorinated liquid crystal molecules. Arrows indicate the orientation of the molecular ...
Figure 15: Di-, tri- and tetra-fluoro liquid crystal molecules 60–62.
Figure 16: Collagen mimics of general formula (Pro-Yaa-Gly)10 where Yaa is either 4(R)-hydroxyproline (63) or ...
Figure 17: Enkephalin-related peptide 64 and the fluorinated analogue 65. The electron-withdrawing trifluorome...
Figure 18: The C–F bond influences the conformation of β-peptides. β-Heptapeptide 66 adopts a helical conforma...
Figure 19: The conformations of pseudopeptides 69 and 70 are influenced by the α-fluoroamide effect and the fl...
Beilstein J. Org. Chem. 2007, 3, No. 32, doi:10.1186/1860-5397-3-32
Graphical Abstract
Scheme 1: Allylsilane-N-acyliminium cyclisation.
Scheme 2: Enantioselective synthesis of (-)-indolizidine 167B by intramolecular allylsilane-N-acyliminium cyc...
Scheme 3: Synthesis of (±)-indolizidine 167B by intermolecular cyclisation of allylsilane-N-acyliminium cycli...
Scheme 4: Synthesis of 3,5-disubstituted indolizidines from L-pyroglutamic acid.
Scheme 5: Access to indolizidine precursors of dendroprimine starting from chiral 2-aminopropanoate.
Scheme 6: Access to (-)-dendroprimine by reduction with LiAlH4 of indolizidinones 26.
Scheme 7: Access to (-)-dendroprimine by catalytic hydrogenation of indolizidinones 26.
Scheme 8: Synthesis of (±)-myrtine and (±)-epimyrtine.
Scheme 9: Enantioselective synthesis of (+)-myrtine and (-)-epimyrtine.
Scheme 10: Synthesis of (±)-lasubines I and II and (±)-2-epilasubine II.
Scheme 11: Synthesis of (±)-lasubine I and II.
Scheme 12: Enantioselective synthesis of (-)-lasubines I and II and (+)-subcosine.